Logo
Nazad
L. Moorthy, E. Roy, V. Kurra, M. Peterson, A. Hassett, T. Lehman, C. Scott, D. El-Ghoneimy, S. Saad, Reem El Feky, S. Al‐Mayouf, P. Doležalová, H. Malcová, T. Herlin, S. Nielsen, N. Wulffraat, A. van Royen, S. Marks, A. Belot, J. Brunner, C. Huemer, I. Foeldvari, G. Horneff, Traudel Saurenman, S. Schroeder, P. Pratsidou-Gertsi, M. Trachana, Y. Uziel, A. Aggarwal, T. Constantin, R. Cimaz, T. Giani, L. Cantarini, F. Falcini, S. M. Manzoni, A. Ravelli, D. Rigante, F. Zulian, T. Miyamae, S. Yokota, J. Sato, C. Magalhaes, C. Len, S. Appenzeller, S. Knupp, M. Rodrigues, F. Sztajnbok, R. D. de Almeida, A. D. de Jesus, Lúcia Maria de Arruda Campos, C. Silva, C. Lazar, G. Sušić, T. Avčin, R. Cuttica, R. Burgos-Vargas, E. Faugier, J. Antón, C. Modesto, L. Vázquez, Lilliana Barillas, L. Barinstein, G. Sterba, I. Maldonado, S. Ozen, O. Kasapcopur, E. Demirkaya, S. Benseler
6 25. 11. 2014.

Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration

BackgroundRheumatic diseases in children are associated with significant morbidity andpoor health-related quality of life (HRQOL). There is no health-relatedquality of life (HRQOL) scale available specifically for children with lesscommon rheumatic diseases. These diseases share several features withsystemic lupus erythematosus (SLE) such as their chronic episodic nature,multi-systemic involvement, and the need for immunosuppressive medications.HRQOL scale developed for pediatric SLE will likely be applicable tochildren with systemic inflammatory diseases.FindingsWe adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters(SMILEY©) to Simple Measure of Impact of Illness in Youngsters(SMILY©-Illness) and had it reviewed by pediatric rheumatologists forits appropriateness and cultural suitability. We tested SMILY©-Illnessin patients with inflammatory rheumatic diseases and then translated it into28 languages.Nineteen children (79% female, n=15) and 17 parents participated. The meanage was 12±4 years, with median disease duration of 21 months (1-172months). We translated SMILY©-Illness into the following 28 languages:Danish, Dutch, French (France), English (UK), German (Germany), German(Austria), German (Switzerland), Hebrew, Italian, Portuguese (Brazil),Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish(Argentina), Spanish (Mexico), Spanish (Venezuela), Turkish, Afrikaans,Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian,Japanese, Romanian, Serbian and Xhosa.ConclusionSMILY©-Illness is a brief, easy to administer and score HRQOL scale forchildren with systemic rheumatic diseases. It is suitable for use acrossdifferent age groups and literacy levels. SMILY©-Illness with itsavailable translations may be used as useful adjuncts to clinical practiceand research.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više